Expression of autocrine motility factor mRNA is a poor prognostic factor in high-grade astrocytoma

Pathology International

Volumn 56, Issue 9, 2006, Pages 510-515

  Tanizaki, Yoshinori ^a   Sato, Yuichi ^b   Oka, Hidehiro ^a   Utsuki, Satoshi ^a   Kondo, Koji ^a   Miyajima, Yoshiteru ^a   Nagashio, Ryo ^b   Fujii, Kiyotaka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Astrocytoma; Autocrine motility factor; gp78; In situ hybridization; Prognosis

Indexed keywords

AUTOCRINE MOTILITY FACTOR; AUTOCRINE MOTILITY FACTOR RECEPTOR; FORMALDEHYDE; GLYCOPROTEIN; GLYCOPROTEIN GP 78; MESSENGER RNA; PARAFFIN; UNCLASSIFIED DRUG;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER INFILTRATION; CANCER SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCATION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ASTROCYTOMA; AUTOCRINE MOTILITY FACTOR; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, CYTOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33747475496     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2006.01999.x     Document Type: Article

References (33)

1. Liotta LA, Mandler R, Murano G et al. Tumor cell autocrine motility factor. Proc Natl Acad Sci USA 1986; 83: 3302-6.
2. Yanagawa T, Funasaka T, Tsutsumi S, Watanabe H, Raz A. Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy. Endocr Relat Cancer 2004; 11: 749-59.
3. Shimizu K, Tani M, Watanabe H et al. The autocrine motility factor receptor gene encodes a novel type of seven transmembrane protein. FEBS Lett 1999; 456: 295-300.
4. Tsutsumi S, Gupta SK, Hogan V, Collard JG, Raz A. Activation of small GTPase Rho is required for autocrine motility factor signaling. Cancer Res 2002; 62: 4484-90.
5. Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004; 70: 217-28.
6. Haga A, Funasaka T, Niinaka Y, Raz A, Nagase H. Autocrine motility factor signaling induces tumor apoptotic resistance by regulations Apaf-1 and Caspase-9 apoptosome expression. Int J Cancer 2003; 107: 707-14.
7. Tsutsumi S, Yanagawa T, Shimura T et al. Regulation of cell proliferation by autocrine motility factor/phosphoglucose isomerase signaling. J Biol Chem 2003; 278: 32165-72.
8. Joy AM, Beaudry CE, Tran NL et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003; 116: 4409-17.
9. Gong W, Jiang Y, Wang L et al. Expression of autocrine motility factor correlates with the angiogenic phenotype of and poor prognosis for human gastric cancer. Clin Cancer Res 2005; 11: 5778-83.
10. Tsutsumi S, Yanagawa T, Shimura T, Kuwano H, Raz A. Autocrine motility factor signaling enhances pancreatic cancer metastasis. Clin Cancer Res 2004; 10: 7775-84.
11. Takanami I, Takeuchi K. Autocrine motility factor-receptor gene expression in lung cancer. Jpn J Thorac Cardiovasc Surg 2003; 51: 368-73.
12. Jiang WG, Raz A, Douglas-Jones A, Mansel RE. Expression of Autocrine Motility Factor (AMF) and its receptor, AMFR, in human breast cancer. J Histochem Cytochem 2006; 54: 231-41.
13. Newton HB, Fleisher M, Schwartz MK, Malkin MG. Glucose-phosphate isomerase as a CSF marker for leptomeningeal metastasis. Neurology 1991; 41: 395-8.
14. Wada C, Kasai K, Kameya T, Ohtani H. A general transcription initiation factor, human transcription factor IID, overexpressed in human lung and breast carcinoma and rapidly induced with serum stimulation. Cancer Res 1992; 52: 307-13.
15. Divjak M, Glare EM, Walters EH. Improvement of non-radioactive in situ hybridization in human airway tissues: Use of PCR-generated templates for synthesis of probes and an antibody sandwich technique for detection of hybridization. J Histochem Cytochem 2002; 50: 541-8.
16. Suzuki T, Kadoya Y, Sato Y et al. The expression of pancreatic endocrine markers in centroacinar cells of the normal and regenerating rat pancreas: Their possible transformation to endocrine cells. Arch Histol Cytol 2003; 66: 347-58.
17. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Nervous System. Lyon: IARC, 2000; 29-39.
18. Smith JS, Tachibana I, Passe SM et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93: 1246-56.
19. Kirla R, Salminen E, Huhtala S et al. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy. J Neurooncol 2000; 46: 71-80.
20. Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H. Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir (Wien) 2001; 143: 159-66.
21. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
22. Utsuki S, Sato Y, Oka H, Tsuchiya B, Suzuki S, Fujii K. Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas. J Neurooncol 2002; 57: 187-92.
23. Torimura T, Ueno T, Kin M et al. Autocrine motility factor enhances hepatoma cell invasion across the basement membrane through activation of beta1 integrins. Hepatology 2001; 34: 62-71.
24. Kawanishi K, Doki Y, Shiozaki H et al. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers. Am J Clin Pathol 2000; 113: 266-74.
25. Brat DJ, Castellano-Sanchez AA, Hunter SB et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920-27.
26. Borgwardt L, Hojgaard L, Carstensen H et al. Increased fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: A study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 2005; 23: 3030-37.
27. Sminia P, Acker H, Eikesdal HP et al. Oxygenation and response to irradiation of organotypic multicellular spheroids of human glioma. Anticancer Res 2003; 23: 1461-6.
28. Liang BC. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 1996; 29: 149-55.
29. Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: A complex network. Biochim Biophys Acta 2005; 1755: 107-20.
30. Evans SM, Judy KD, Dunphy I et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004; 10: 8177-84.
31. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors: Association with angiogenesis, invasion, and progression. Cancer 2000; 88: 2606-18.
32. Funasaka T, Yanagawa T, Hogan V, Raz A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J 2005; 19: 1422-30.
33. Krishnamachary B, Berg-Dixon S, Kelly B et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63: 1138-43.